Screener
Novavax NVAX Supply sales — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The source filing: Novavax’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001000694-26-000018
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Product sales | ||||
| Nuvaxovid™ sales(1) | — | $(2,093) | $9,558 | $605,931 |
| Supply sales(2) | 18,854 | 12,817 | 51,496 | 26,471 |
| Total Product sales | $18,854 | $10,724 | $61,054 | $632,402 |
Item 1. Consolidated Financial Statements
FAQ
- What is Novavax's supply sales — total revenue?
- Novavax (NVAX) reported supply sales — total revenue of $18.85M in Q2 2026.
- How has Novavax's supply sales — total revenue changed year-over-year?
- Novavax's supply sales — total revenue increased by 47.1% year-over-year, from $12.82M to $18.85M.
- What is the long-term trend for Novavax's supply sales — total revenue?
- Over 2 years (2023 to 2025), Novavax's supply sales — total revenue has grown at a 90.5% compound annual growth rate (CAGR), from $16.5M to $59.86M.
- What does supply sales — total revenue mean?
- This metric represents the total gross revenue generated from the direct sale and distribution of vaccine products or related biological supplies to customers. It reflects the commercial performance and market adoption of the company's clinical-stage or approved vaccine portfolio. Monitoring this revenue stream provides insight into the company's ability to monetize its biotechnology research and transition from development to commercial-scale operations.
Ask your AI about Novavax's supply sales — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude